Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 45321 results
Neos Therapeutics gets key patent covering extended release oral disintegrating tablet (XR-ODT) platform technology
Neos Therapeutics, a specialty pharmaceutical company with a portfolio of novel and proprietary oral drug delivery technologies as well as a late-stage pipeline of innovative extended release products for Attention Deficit Hyperactivity Disorder, has been granted a key patent (US Patent No. 8,840,924) covering its XR-oral disintegrating tablet technology, known as Rapidly Disintegrating Ionic Masking.
News
Aciex announces issuance of separate US patents covering two leading product candidates
Aciex Therapeutics has announced that the US Patent and Trademark Office (USPTO) has issued a US Patent (No. 8,829,005) covering AC-170 Cetirizine Ophthalmic Compositions and a US Patent (No. 8,765,725) covering AC-155 Fluticasone Propionate Nano-crystalline Compositions.
News
Blaze Bioscience gets SBIR phase II funding for clinical trial of tumor paint BLZ-100 in sarcoma
Blaze Bioscience, a biotechnology company focused on guided cancer therapy, has been awarded a $1.5m Small Business Innovation Research (SBIR) Phase II contract from the National Cancer Institute (NCI) to study Tumor Paint BLZ-100 in patients with soft tissue sarcoma.
News
Aphios granted US patent for nanotechnology formulation of poorly soluble drugs
Aphios has announced that it has been granted United States Patent No. 8,703,727 entitled “Nanotechnology Formulation of Poorly Soluble Compounds,” for difficult to formulate and deliver drugs.
News
Teva announces initiation of NDA and positive results from second human abuse liability study for CEP-33237
Teva Pharmaceutical Industries announced the initiation of a rolling New Drug Application (NDA) submission to the US Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties (CEP-33237) as allowed for fast track designated products.
News
Novartis' Lucentis obtains Health Canada approval for visual impairment due to CNV
By PBR Staff Writer
Novartis Pharmaceuticals Canada has received approval from Health Canada for Lucentis (ranibizumab) to treat visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).
News
Dilafor, Opocrin sign supply and partnership deal for tafoxiparin
By PBR Staff Writer
Swedish drug development firm Dilafor has entered into a commercial supply and partnership agreement with Italy-based Opocrin for its polysaccharide derivative, tafoxiparin drug candidate.
News
Amgen reports positive Phase III trial results of ABP 501 in plaque psoriasis patients
By PBR Staff Writer
Amgen has reported positive results from its Phase III trial of biosimilar candidate ABP 501 in patients with moderate-to-severe plaque psoriasis.
News
EMD Serono, ICR, Wellcome Trust collaborate to develop anti-cancer drugs
By PBR Staff Writer
Merck subsidiary EMD Serono, the Institute of Cancer Research (ICR) and the Wellcome Trust have entered into a co-development and license agreement for developing new drug candidates to treat different forms of cancer.
News
Pinnacle begins Phase III bile duct cancer trial of PHOTOFRIN
By PBR Staff Writer
Concordia Healthcare subsidiary Pinnacle Biologics has started an open-label, multicenter Phase III trial (OPUS) designed to evaluate the efficacy and safety of Photodynamic therapy (PDT) with PHOTOFRIN (porfimer sodium) for injection to treat cholangiocarcinoma (CCA).
News
Bio-Path completes cohort six of liposomal Grb-2 Phase I trial for blood cancers
By PBR Staff Writer
US-based biotechnology firm Bio-Path Holdings has completed cohort six of its Phase I clinical trial evaluating lead compound, Liposomal Grb-2, in blood cancers.
News
BrainStorm's NurOwn obtains FDA fast track status for amyotrophic lateral sclerosis
By PBR Staff Writer
BrainStorm Cell Therapeutics (BCLI) has received fast track status from the US Food and Drug Administration (FDA) for NurOwn to treat amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease.
News
DNAtrix’s DNX-2401 gets FDA orphan drug status to treat malignant glioma
By PBR Staff Writer
US-based DNAtrix has secured Orphan Drug Designation from the US Food and Drug Administration (FDA) for DNX-2401, a conditionally-replicative oncolytic adenovirus for the treatment of malignant glioma.
News
DiscoveryBioMed awarded Dual SBIR awards for PKD drug discovery and validation
DiscoveryBioMed learned in recent months that it was awarded a new Phase 1 SBIR grant from the National Institutes of Health (NIH) to perform high-throughput screening (HTS)-based drug discovery and validation to discover novel small molecules that attack the secondary phase of autosomal dominant polycystic kidney disease (ADPKD).
News
FDA warns consumers about some OTC medicines over possible impair driving
By PBR Staff Writer
The US Food and Drug administration (FDA) has cautioned consumers that the use of some common over-the counter (OTC) medications can make them drowsy and affect their ability to drive and operate machinery safely.
News
136-150 of 45321 results